BCM
IPSC icon

Bridgeway Capital Management’s Century Therapeutics IPSC Stock Holding History

Bridgeway Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,700
Closed -$14.9K – 1248
2025
Q2 		$14.9K Sell
26,700
-93,800
-78% -$50.3K ﹤0.01% 1169
2025
Q1 		$57.4K Sell
120,500
-129,200
-52% -$97.1K ﹤0.01% 1112
2024
Q4 		$252K Sell
249,700
-7,900
-3% -$10.8K 0.01% 959
2024
Q3 		$440K Buy
257,600
+100,000
+63% +$196K 0.01% 893
2024
Q2 		$402K Buy
157,600
+40,000
+34% +$126K 0.01% 909
2024
Q1 		$492K Sell
117,600
-2,500
-2% -$10.6K 0.01% 937
2023
Q4 		$399K Sell
120,100
-44,900
-27% -$81.8K 0.01% 995
2023
Q3 		$330K Hold
165,000
– – 0.01% 998
2023
Q2 		$521K Buy
+165,000
New +$532K 0.01% 884

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bridgeway Capital Management's IPSC Position: Q3 2025 in Review

Bridgeway Capital Management sold out of Century Therapeutics (IPSC) in Q3 2025, closing a stake of 26,700 shares — an estimated $14.9K sold.

Bridgeway Capital Management first reported a position in IPSC in Q2 2023 and held it in 9 quarters. The position peaked at $521K in Q2 2023. 57 funds tracked by Wall St. Rank hold IPSC as of Q3 2025.

  • Bridgeway Capital Management reported no remaining Century Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 26,700 Century Therapeutics shares in Q3 2025, an estimated $14.9K.
  • Bridgeway Capital Management first reported a position in Century Therapeutics in Q2 2023 and held it in 9 quarters.
  • Bridgeway Capital Management's Century Therapeutics position peaked at $521K in Q2 2023.
  • 57 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.